Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

Tardive dyskinesia is important in the side-effect profile of antipsychotic medication. The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years. Tardive dyskinesia was assessed by the Abnormal Involunt...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 1999-01, Vol.174 (1), p.23-30
Main Authors: Beasley, Charles M., Dellva, Mary Anne, Tamura, Roy N., Morgenstern, Hal, Glazer, William M., Ferguson, Kevin, Tollefson, Gary D.
Format: Article
Language:English
Subjects:
Antipsychotic Agents - adverse effects
Antipsychotics
Benzodiazepines
Double-Blind Method
Double-blind studies
Drug therapy
Drugs
Dyskinesia
Dyskinesia, Drug-Induced - etiology
Haloperidol
Haloperidol - adverse effects
Humans
Involuntary
Mental disorders
Movement disorders
Olanzapine
Pirenzepine - adverse effects
Pirenzepine - analogs & derivatives
Psychotropic drugs
Risk assessment
Risk Factors
Schizophrenia
Schizophrenia - drug therapy
Survival Analysis
Tardive dyskinesia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tardive dyskinesia is important in the side-effect profile of antipsychotic medication. The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years. Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD), it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated. The relative risk of tardive dyskinesia for the overall follow up period for haloperidol (n = 522) v. olanzapine (n = 1192) was 2.66 (95% CI = 1.50-4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n = 513) and 7.45% with haloperidol (n = 114). The relative risk throughout this follow-up period was 11.37 (95% CI = 2.21-58.60). Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.174.1.23